AU2012249188A1 - Bioactive botanical cosmetic compositions and processes for their production - Google Patents
Bioactive botanical cosmetic compositions and processes for their production Download PDFInfo
- Publication number
- AU2012249188A1 AU2012249188A1 AU2012249188A AU2012249188A AU2012249188A1 AU 2012249188 A1 AU2012249188 A1 AU 2012249188A1 AU 2012249188 A AU2012249188 A AU 2012249188A AU 2012249188 A AU2012249188 A AU 2012249188A AU 2012249188 A1 AU2012249188 A1 AU 2012249188A1
- Authority
- AU
- Australia
- Prior art keywords
- cell
- cosmetic
- fraction
- plant
- cosmetic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 370
- 239000000203 mixture Substances 0.000 title claims abstract description 183
- 238000000034 method Methods 0.000 title claims abstract description 161
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 97
- 230000008569 process Effects 0.000 title description 32
- 238000004519 manufacturing process Methods 0.000 title description 27
- 210000002966 serum Anatomy 0.000 claims abstract description 168
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 125
- 239000012528 membrane Substances 0.000 claims abstract description 118
- 238000009472 formulation Methods 0.000 claims abstract description 30
- 230000000699 topical effect Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 292
- 241000196324 Embryophyta Species 0.000 claims description 204
- 230000000694 effects Effects 0.000 claims description 94
- 239000002028 Biomass Substances 0.000 claims description 86
- 230000003078 antioxidant effect Effects 0.000 claims description 63
- 239000003963 antioxidant agent Substances 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 44
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 40
- 230000010261 cell growth Effects 0.000 claims description 40
- 230000002000 scavenging effect Effects 0.000 claims description 40
- 240000002853 Nelumbo nucifera Species 0.000 claims description 38
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 38
- 239000006228 supernatant Substances 0.000 claims description 38
- 239000000706 filtrate Substances 0.000 claims description 34
- 230000000638 stimulation Effects 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 31
- 235000015724 Trifolium pratense Nutrition 0.000 claims description 29
- 235000013526 red clover Nutrition 0.000 claims description 29
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 239000003755 preservative agent Substances 0.000 claims description 22
- 210000000440 neutrophil Anatomy 0.000 claims description 21
- 108010075031 Cytochromes c Proteins 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 20
- 230000019254 respiratory burst Effects 0.000 claims description 20
- 240000002913 Trifolium pratense Species 0.000 claims description 19
- 238000012545 processing Methods 0.000 claims description 19
- 230000035755 proliferation Effects 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000000926 separation method Methods 0.000 claims description 18
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 17
- 210000000805 cytoplasm Anatomy 0.000 claims description 17
- 102100030497 Cytochrome c Human genes 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 230000001086 cytosolic effect Effects 0.000 claims description 13
- 238000005345 coagulation Methods 0.000 claims description 12
- 230000015271 coagulation Effects 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 238000004448 titration Methods 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims description 7
- 239000004302 potassium sorbate Substances 0.000 claims description 7
- 229940069338 potassium sorbate Drugs 0.000 claims description 7
- 238000007670 refining Methods 0.000 claims description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims description 7
- 239000004299 sodium benzoate Substances 0.000 claims description 7
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical group [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 7
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 7
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 7
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 230000000368 destabilizing effect Effects 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 230000003833 cell viability Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000008309 hydrophilic cream Substances 0.000 claims description 3
- 230000002051 biphasic effect Effects 0.000 claims description 2
- 238000000909 electrodialysis Methods 0.000 claims description 2
- 230000001112 coagulating effect Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 description 225
- 230000005764 inhibitory process Effects 0.000 description 72
- 210000001519 tissue Anatomy 0.000 description 63
- 239000008406 cosmetic ingredient Substances 0.000 description 56
- 210000003491 skin Anatomy 0.000 description 50
- 239000000047 product Substances 0.000 description 43
- 235000006708 antioxidants Nutrition 0.000 description 38
- 240000001432 Calendula officinalis Species 0.000 description 37
- 235000005881 Calendula officinalis Nutrition 0.000 description 37
- 235000002020 sage Nutrition 0.000 description 36
- 238000003556 assay Methods 0.000 description 30
- 230000000813 microbial effect Effects 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 25
- 230000000636 anti-proteolytic effect Effects 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 22
- -1 i.e. Proteins 0.000 description 21
- 239000013641 positive control Substances 0.000 description 21
- 244000178870 Lavandula angustifolia Species 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 240000005979 Hordeum vulgare Species 0.000 description 19
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 18
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 18
- 231100000135 cytotoxicity Toxicity 0.000 description 18
- 230000003013 cytotoxicity Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 235000007340 Hordeum vulgare Nutrition 0.000 description 17
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 17
- 102000035195 Peptidases Human genes 0.000 description 16
- 108091005804 Peptidases Proteins 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- 238000003306 harvesting Methods 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 238000009826 distribution Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 235000019833 protease Nutrition 0.000 description 14
- 239000002994 raw material Substances 0.000 description 14
- 240000007164 Salvia officinalis Species 0.000 description 13
- 102000003425 Tyrosinase Human genes 0.000 description 13
- 108060008724 Tyrosinase Proteins 0.000 description 13
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000219823 Medicago Species 0.000 description 12
- 240000004658 Medicago sativa Species 0.000 description 12
- 235000002912 Salvia officinalis Nutrition 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000005520 cutting process Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 102000016387 Pancreatic elastase Human genes 0.000 description 11
- 108010067372 Pancreatic elastase Proteins 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 230000006641 stabilisation Effects 0.000 description 11
- 238000011105 stabilization Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 102000016799 Leukocyte elastase Human genes 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 239000001102 lavandula vera Substances 0.000 description 10
- 235000018219 lavender Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 108010028275 Leukocyte Elastase Proteins 0.000 description 9
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000227 grinding Methods 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 9
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 238000002803 maceration Methods 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 7
- 235000010624 Medicago sativa Nutrition 0.000 description 7
- 206010067482 No adverse event Diseases 0.000 description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 6
- 101800003838 Epidermal growth factor Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 238000005273 aeration Methods 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 230000002849 elastaseinhibitory effect Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 229940116977 epidermal growth factor Drugs 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000002427 irreversible effect Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 210000004927 skin cell Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 5
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 5
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 5
- 238000007696 Kjeldahl method Methods 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000002753 trypsin inhibitor Substances 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000208838 Asteraceae Species 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000220485 Fabaceae Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 241000207923 Lamiaceae Species 0.000 description 4
- 241000209504 Poaceae Species 0.000 description 4
- 241000589774 Pseudomonas sp. Species 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000007398 colorimetric assay Methods 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 235000021374 legumes Nutrition 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- 235000012680 lutein Nutrition 0.000 description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 4
- 239000001656 lutein Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 4
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000607149 Salmonella sp. Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 102000056189 Neutrophil collagenases Human genes 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037898 Rash vesicular Diseases 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003602 elastase inhibitor Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000001056 green pigment Substances 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 238000005360 mashing Methods 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 2
- DEOKFPFLXFNAON-NTISSMGPSA-N n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]benzamide;hydrochloride Chemical compound Cl.N([C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-NTISSMGPSA-N 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 239000012875 nonionic emulsifier Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000012599 radical scavenging assay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002568 urticarial effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- KNDAEDDIIQYRHY-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(piperazin-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCNCC1 KNDAEDDIIQYRHY-UHFFFAOYSA-N 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 101100134298 Bacillus subtilis (strain 168) nucA gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001067407 Cometes Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 108040001319 catechol oxidase activity proteins Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 108010058393 monophenolase Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017202660A AU2017202660A1 (en) | 2011-02-22 | 2017-04-21 | Bioactive botanical cosmetic compositions and processes for their production |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/032,187 | 2011-02-22 | ||
| US13/032,187 US8277852B2 (en) | 2002-01-25 | 2011-02-22 | Bioactive botanical cosmetic compositions and processes for their production |
| PCT/US2012/025899 WO2012148527A2 (en) | 2011-02-22 | 2012-02-21 | Bioactive botanical cosmetic compositions and processes for their production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017202660A Division AU2017202660A1 (en) | 2011-02-22 | 2017-04-21 | Bioactive botanical cosmetic compositions and processes for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2012249188A1 true AU2012249188A1 (en) | 2013-09-05 |
Family
ID=46025863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012249188A Abandoned AU2012249188A1 (en) | 2011-02-22 | 2012-02-21 | Bioactive botanical cosmetic compositions and processes for their production |
| AU2017202660A Abandoned AU2017202660A1 (en) | 2011-02-22 | 2017-04-21 | Bioactive botanical cosmetic compositions and processes for their production |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017202660A Abandoned AU2017202660A1 (en) | 2011-02-22 | 2017-04-21 | Bioactive botanical cosmetic compositions and processes for their production |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8277852B2 (enExample) |
| EP (1) | EP2677999B1 (enExample) |
| JP (2) | JP6246593B2 (enExample) |
| KR (1) | KR20140019346A (enExample) |
| CN (2) | CN103547253A (enExample) |
| AU (2) | AU2012249188A1 (enExample) |
| BR (1) | BR112013021274A2 (enExample) |
| CA (1) | CA2827773A1 (enExample) |
| MY (1) | MY172073A (enExample) |
| WO (1) | WO2012148527A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442391B2 (en) * | 2002-01-25 | 2008-10-28 | Integrated Botanical Technologies, Llc | Bioactive botanical cosmetic compositions and processes for their production |
| US8277852B2 (en) * | 2002-01-25 | 2012-10-02 | Akzo Nobel Surface Chemistry Llc | Bioactive botanical cosmetic compositions and processes for their production |
| CN103402494B (zh) * | 2011-02-22 | 2017-01-18 | 宝洁公司 | 使用包含榕树、莲花和三叶草浆液组分的组合物改善老化皮肤外观的方法 |
| CN102949299B (zh) * | 2011-12-20 | 2014-08-06 | 上海莱博生物科技有限公司 | 荷叶碱或含其的植物提取物的应用 |
| KR20150083996A (ko) * | 2012-11-14 | 2015-07-21 | 아크조 노벨 케미칼즈 인터내셔널 비.브이. | 생활성 식물 조성물의 제조 방법, 및 상기 방법으로 제조되는 조성물 |
| KR101394430B1 (ko) | 2012-12-26 | 2014-05-14 | 시흥시 | 연근 추출물이 함유된 화장품 제조방법 |
| SG11201506444RA (en) * | 2013-03-13 | 2015-09-29 | Akzo Nobel Chemicals Int Bv | Bioactive botanical compositions and uses thereof |
| AU2014230873B2 (en) * | 2013-03-15 | 2016-10-06 | Isp Investments Inc. | Bioactive compositions from fruit and methods for their production |
| CN104473832A (zh) * | 2014-11-17 | 2015-04-01 | 青岛厚科信息工程有限公司 | 一种抗菌洁面乳及其制备方法 |
| US11154492B2 (en) * | 2016-01-15 | 2021-10-26 | Isp Investments Llc | Bioactive compositions from ginseng plant (Panax spp.) and methods for their production and use |
| KR20180115751A (ko) | 2016-02-25 | 2018-10-23 | 아이에스피 인베스트먼츠 엘엘씨 | 살아있는 식물로부터 수득한 성분에 의한 태양광의 유해 효과의 완화 |
| ITUA20162223A1 (it) * | 2016-04-01 | 2017-10-01 | Linnea Sa | Composizione topica comprendente estratti vegetali |
| EP3509706B1 (en) * | 2016-09-07 | 2021-11-03 | ISP Investments LLC | Method for increasing lipolysis using a composition comprising bioactive nelumbo nucifera (lotus) extract |
| CN114788791A (zh) | 2017-06-23 | 2022-07-26 | 宝洁公司 | 用于改善皮肤外观的组合物和方法 |
| HU231226B1 (hu) * | 2018-01-31 | 2022-03-28 | Debreceni Egyetem | Növényifehérje-koagulum előállítására szolgáló eljárás |
| US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
| CN110876702A (zh) * | 2019-12-09 | 2020-03-13 | 健民药业集团股份有限公司 | 红车轴草提取物用作酪氨酸酶抑制剂的用途 |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2559459A (en) * | 1949-02-01 | 1951-07-03 | Western Condensing Co | Vegetable treatment process |
| US3849391A (en) * | 1969-02-17 | 1974-11-19 | Grain Processing Corp | Recovery of protein |
| US3684520A (en) * | 1969-12-09 | 1972-08-15 | Us Agriculture | Fractionation of leafy green crops |
| US3775133A (en) * | 1971-08-02 | 1973-11-27 | W Batley | Fractionation of alfalfa wetted with molasses serum |
| US3821346A (en) * | 1971-08-02 | 1974-06-28 | W Batley | Pet litter produced by recycled molasses serum |
| US3957774A (en) * | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
| US3799806A (en) * | 1972-04-20 | 1974-03-26 | Danske Sukkerfab | Process for the purification and clarification of sugar juices,involving ultrafiltration |
| US3823128A (en) * | 1972-05-16 | 1974-07-09 | Us Agriculture | Preparation of edible protein from leafy green crops such as alfalfa |
| US4006078A (en) * | 1974-07-08 | 1977-02-01 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of soluble edible protein from leafy green crops |
| US3959246A (en) * | 1974-07-08 | 1976-05-25 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of soluble edible protein from leafy green crops |
| FR2294647A1 (fr) * | 1974-11-04 | 1976-07-16 | France Luzerne | Procede de traitement de vegetaux verts feuillus en vue d'une extraction de proteines dans les jus de pressage et d'une deshydratation economique du tourteau |
| GB1430566A (en) * | 1974-11-15 | 1976-03-31 | Nestel Sa | Isolation of proteins |
| US3993794A (en) * | 1976-01-15 | 1976-11-23 | The United States Of America As Represented By The Secretary Of Agriculture | Method for texturizing proteins |
| HU174943B (hu) | 1976-06-30 | 1980-04-28 | Vepex Foevallalkozasi Iroda Rt | Sposob poluchenija koncentratov rastitel'nogo belka i pigmenta |
| US4077950A (en) * | 1976-07-12 | 1978-03-07 | Source Proteins, Inc. | Process for the recovery of substantially water-soluble non-toxic protein compounds from fresh non-woody vegetation |
| US4250197A (en) * | 1976-10-25 | 1981-02-10 | Vepex Fovallalkopasi Iroda Rt. | Method for processing plant protein |
| US4130553A (en) * | 1977-01-05 | 1978-12-19 | Batley Jr William R | Process for improving the nutritional value of green plant protein |
| US4178372A (en) * | 1978-03-06 | 1979-12-11 | Coats Billy C | Hypoallergenic stabilized aloe vera gel |
| CA1099576A (en) * | 1978-03-23 | 1981-04-21 | Chester D. Myers | Improved process for isolation of proteins |
| US4234620A (en) * | 1978-12-26 | 1980-11-18 | A. E. Staley Manufacturing Company | Water-soluble vegetable protein aggregates |
| GB2054343B (en) | 1979-07-20 | 1983-08-24 | Energiagazdalkodasi Intezet | Preserving green vegetable matter |
| US4347324A (en) * | 1979-09-24 | 1982-08-31 | Leaf Proteins, Inc. | Process for isolation of proteins from plant leaves |
| EP0063124B1 (fr) * | 1980-08-13 | 1985-02-06 | Verniers S.A. | Procede d'obtention de jus clairs de vegetaux et de recuperation de constituants valorisables |
| US4359530A (en) * | 1980-09-08 | 1982-11-16 | Aluminum Company Of America | Protein extraction from green crops |
| US4334024A (en) * | 1980-11-03 | 1982-06-08 | Sarjit Johal | Preparation and crystallization of fraction I protein from plant sources |
| JPS5914451B2 (ja) | 1981-03-09 | 1984-04-04 | 日本薬品開発株式会社 | 植物緑葉源抗炎症剤 |
| US4333871A (en) * | 1981-03-18 | 1982-06-08 | International Harvester Company | Coagulation method for preparing leaf protein concentrates (LPC) from plant foliage |
| US4421682A (en) * | 1981-04-06 | 1983-12-20 | The United States Of America As Represented By The Secretary Of Agriculture | Heating of proteinaceous liquids |
| FR2523976B1 (fr) * | 1982-03-26 | 1985-08-30 | Pasteur Institut | Nouveau produit proteique, obtention et application comme medicament, en particulier immunoregulateur et antiallergique |
| US4588691A (en) * | 1984-02-29 | 1986-05-13 | Johal Sarjit S | Method for preparation of Fraction I protein and by-products thereof |
| CH671322A5 (enExample) * | 1986-09-29 | 1989-08-31 | Bucher Guyer Ag Masch | |
| FR2632308B1 (fr) * | 1988-06-07 | 1991-08-16 | Fondation Nale Transfusion San | Procede et installation de fractionnement en continu de proteines vegetales animales ou humaines |
| JPH111686A (ja) | 1990-05-14 | 1999-01-06 | Yoshihide Hagiwara | 抗酸化剤 |
| US5723149A (en) * | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
| JP2986565B2 (ja) * | 1991-02-04 | 1999-12-06 | 御木本製薬株式会社 | 化粧料 |
| US6221363B1 (en) * | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
| US5798446A (en) * | 1991-10-10 | 1998-08-25 | Nupron Gmbh Proteinwerk | Method of extracting proteins utilizable in foodstuff from a protein-containing substance |
| JPH05229921A (ja) | 1992-02-21 | 1993-09-07 | Nakano Vinegar Co Ltd | 発毛促進用組成物 |
| CH684924A5 (de) * | 1993-04-02 | 1995-02-15 | Bucher Guyer Ag Masch | Verfahren zum Trennen fester und flüssiger Anteile, sowie Vorrichtung zu dessen Durchführung. |
| US5433968A (en) * | 1993-04-23 | 1995-07-18 | Nestec S.A. | Process for producing a simulated meat product |
| US6123973A (en) * | 1993-07-30 | 2000-09-26 | Tillin, Inc. | Methods of preparation and using antimicrobial products |
| ATE163838T1 (de) * | 1993-08-17 | 1998-03-15 | Nestle Sa | Verfahren zum extrahieren von pflanzlicher antioxidanten in flüssiger form |
| US5777080A (en) * | 1994-05-09 | 1998-07-07 | The Board Of Trustees Of The University Of Arkansas | Highly soluble protein, method for making, and food products made thereof |
| AR002779A1 (es) * | 1995-07-10 | 1998-04-29 | Nestle Sa | Procedimiento para fabricar una leche de almendras de frutas. |
| US5925348A (en) * | 1996-02-23 | 1999-07-20 | Medical Doctor's Research Institute, Inc. | Methods utilizing compositions containing sacred lotus (methyltransferase) to treat aging skin |
| US6468564B1 (en) * | 1997-02-21 | 2002-10-22 | Clientele Beauty, Inc. | Topical compositions containing lotus for skin treatment |
| FR2751878B1 (fr) * | 1996-07-30 | 1998-09-04 | Oreal | Utilisation dans une composition d'un extrait d'au moins une labiee |
| EP0821967A1 (en) * | 1996-08-02 | 1998-02-04 | Institute For Advanced Skin Research Inc. | Composition for enhancing hyaluronic acid productivity and method for preparing same |
| JP3457813B2 (ja) * | 1996-11-07 | 2003-10-20 | 花王株式会社 | 化粧料 |
| IT1288257B1 (it) * | 1996-11-29 | 1998-09-11 | Paoli Ambrosi Gianfranco De | Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico |
| FR2769502B1 (fr) * | 1997-10-14 | 2000-04-14 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.) |
| US6037456A (en) * | 1998-03-10 | 2000-03-14 | Biosource Technologies, Inc. | Process for isolating and purifying viruses, soluble proteins and peptides from plant sources |
| JPH11279069A (ja) * | 1998-03-27 | 1999-10-12 | Ichimaru Pharcos Co Ltd | 活性酸素消去剤 |
| US5994508A (en) * | 1998-04-13 | 1999-11-30 | Protein Technologies International, Inc. | Isoflavone rich protein isolate and process for producing |
| US6013771A (en) * | 1998-06-09 | 2000-01-11 | Protein Technologies International, Inc. | Isoflavone rich protein isolate and process for producing |
| DK1002521T3 (da) * | 1998-11-19 | 2002-11-11 | Isernhagen Heilmittelbetr Gmbh | Anvendelse af udtræk opnået ved ekstraktion med kuldioxid som deodoranter |
| JP2001122757A (ja) * | 1999-10-22 | 2001-05-08 | Naris Cosmetics Co Ltd | 活性酸素消去剤、抗酸化剤および化粧料 |
| US6436417B1 (en) * | 2001-06-25 | 2002-08-20 | Blistex Inc. | Acne treatment compositions |
| JP2003048846A (ja) * | 2001-07-31 | 2003-02-21 | Koei Kogyo Kk | コラゲナーゼ阻害剤及び抗老化用化粧料 |
| US7442391B2 (en) * | 2002-01-25 | 2008-10-28 | Integrated Botanical Technologies, Llc | Bioactive botanical cosmetic compositions and processes for their production |
| US8277852B2 (en) * | 2002-01-25 | 2012-10-02 | Akzo Nobel Surface Chemistry Llc | Bioactive botanical cosmetic compositions and processes for their production |
| EP1344516A1 (de) * | 2002-03-12 | 2003-09-17 | Cognis Iberia, S.L. | Antioxidative Zubereitungen |
| WO2004017934A1 (de) * | 2002-08-16 | 2004-03-04 | Coty B.V. | Hautglättendes kosmetikum auf basis von pflanzenextrakten |
| JP2004231558A (ja) * | 2003-01-30 | 2004-08-19 | Nonogawa Shoji Kk | 美白用皮膚外用剤 |
| DE10329004A1 (de) * | 2003-06-27 | 2005-01-13 | Kaanya Cosmetics Gmbh | Kosmetisches Verfahren zur Verminderung sichtbarer Alterungszeichen der Haut |
| US7233210B2 (en) * | 2003-08-26 | 2007-06-19 | Toshiba America Electric Components, Inc. | Spread spectrum clock generator |
| DE60333873D1 (de) * | 2003-10-03 | 2010-09-30 | Green Meadows Res Llc | Zubereitungen die Lotusextrakte und Methyldonatoren enthalten |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| US7473435B2 (en) * | 2004-01-12 | 2009-01-06 | Integrated Botanical Technologies, Llc | Bioactive compositions form Theacea plants and processes for their production and use |
| DE102005030864A1 (de) * | 2005-07-01 | 2007-01-25 | Beiersdorf Ag | Kosmetische Zubereitung zur Verbesserung der Hautfeuchtigkeit |
| AU2007217003B2 (en) * | 2006-02-21 | 2013-04-04 | Isp Investments Inc. | Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production |
| KR100828193B1 (ko) * | 2006-11-06 | 2008-05-08 | 박영준 | 연 추출물을 함유하는 미백, 노화방지 및 주름개선용조성물 |
| JP5212969B2 (ja) * | 2007-09-25 | 2013-06-19 | ゲオール化学株式会社 | クロマン化合物およびその製造方法 |
| KR101483440B1 (ko) * | 2008-05-02 | 2015-01-19 | (주)아모레퍼시픽 | 포제를 활용한 약용식물 추출물 및 이를 함유하는 피부외용제 조성물 |
| KR101121980B1 (ko) * | 2009-03-03 | 2012-03-09 | 김포시(농업기술센터) | 연잎 추출물 제조방법 및 이에 따른 연잎 추출물 및 이를 함유하는 화장료 조성물 |
| JP2011020965A (ja) * | 2009-07-17 | 2011-02-03 | Maruzen Pharmaceut Co Ltd | 化粧料キット及び化粧方法 |
| CN101658470B (zh) * | 2009-09-18 | 2012-02-22 | 北京欧凯纳斯科技有限公司 | 一种保湿霜及其制备方法 |
-
2011
- 2011-02-22 US US13/032,187 patent/US8277852B2/en not_active Expired - Fee Related
-
2012
- 2012-02-21 KR KR1020137024041A patent/KR20140019346A/ko not_active Abandoned
- 2012-02-21 CA CA2827773A patent/CA2827773A1/en not_active Abandoned
- 2012-02-21 CN CN201280019509.XA patent/CN103547253A/zh active Pending
- 2012-02-21 AU AU2012249188A patent/AU2012249188A1/en not_active Abandoned
- 2012-02-21 WO PCT/US2012/025899 patent/WO2012148527A2/en not_active Ceased
- 2012-02-21 CN CN201710573392.4A patent/CN107320375A/zh active Pending
- 2012-02-21 BR BR112013021274-8A patent/BR112013021274A2/pt not_active Application Discontinuation
- 2012-02-21 EP EP12718432.3A patent/EP2677999B1/en active Active
- 2012-02-21 MY MYPI2013701472A patent/MY172073A/en unknown
- 2012-02-21 JP JP2013555483A patent/JP6246593B2/ja active Active
- 2012-10-01 US US13/632,497 patent/US8668939B2/en not_active Expired - Lifetime
-
2017
- 2017-02-01 JP JP2017016696A patent/JP2017125018A/ja active Pending
- 2017-04-21 AU AU2017202660A patent/AU2017202660A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017125018A (ja) | 2017-07-20 |
| WO2012148527A2 (en) | 2012-11-01 |
| NZ614287A (en) | 2015-05-29 |
| US8277852B2 (en) | 2012-10-02 |
| CN107320375A (zh) | 2017-11-07 |
| KR20140019346A (ko) | 2014-02-14 |
| US20110212190A1 (en) | 2011-09-01 |
| EP2677999B1 (en) | 2018-12-26 |
| MY172073A (en) | 2019-11-13 |
| CN103547253A (zh) | 2014-01-29 |
| WO2012148527A3 (en) | 2013-09-26 |
| BR112013021274A2 (pt) | 2018-07-03 |
| US8668939B2 (en) | 2014-03-11 |
| AU2017202660A1 (en) | 2017-05-11 |
| EP2677999A2 (en) | 2014-01-01 |
| CA2827773A1 (en) | 2012-11-01 |
| JP2014506594A (ja) | 2014-03-17 |
| JP6246593B2 (ja) | 2017-12-13 |
| US20130028996A1 (en) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8277852B2 (en) | Bioactive botanical cosmetic compositions and processes for their production | |
| US8663712B2 (en) | Bioactive botanical cosmetic compositions and processes for their production | |
| KR101224697B1 (ko) | 테아세아 식물로부터의 생물활성 조성물 및 이들의 생산방법 및 용도 | |
| KR102085422B1 (ko) | 강황 추출물과 동백 오일을 함유하는 화장료 조성물 및 피부 외용제 조성물 | |
| WO2012014901A1 (ja) | カルボニル化抑制剤 | |
| JP2006225286A (ja) | Ｄｐｐｈラジカル補足剤、ｓｏｄ活性様作用剤、美白剤、ｌ−ｄｏｐａ自動酸化抑制剤、コラゲナーゼ活性阻害剤 | |
| KR101027113B1 (ko) | 해송의 송기 추출물을 함유하는 화장료 조성물의 제조방법 | |
| KR101954275B1 (ko) | 골드키위 껍질 및 용과 껍질의 복합 추출물을 유효 성분으로 함유하는 화장료 조성물 및 이의 제조 방법 | |
| KR102487267B1 (ko) | 아스타잔틴 복합 성분을 유효성분으로 포함하는 항염증용 화장료 조성물 | |
| WO2003063803A1 (en) | Bioactive botanical cosmetic ingredients and processes for their production | |
| Dueva-Koganov | Bioactive botanical cosmetic compositions and processes for their production | |
| KR102787926B1 (ko) | 오크라 점액 추출물과 알로에 속 식물 점액 추출물을 포함하는 피부 상태 개선용 화장료 조성물 | |
| KR20200062726A (ko) | 적과자두 추출물을 포함하는 항산화, 항주름 및 항염증용 조성물 | |
| KR20090097232A (ko) | 가막살나무 추출물을 포함하는 피부주름 개선용 화장료조성물 | |
| KR20050003602A (ko) | 백산차 추출물을 함유하는 피부 노화 방지 화장료 조성물 | |
| NZ614287B2 (en) | Bioactive botanical cosmetic compositions and processes for their production | |
| KR20220090815A (ko) | 노린재나무 열매 추출물을 포함하는 자외선에 의한 피부세포 손상의 예방 또는 개선용 조성물 | |
| JP2023128847A (ja) | 活性酸素消去剤、糖化抑制剤、カルボニル化抑制剤、ニトロ化抑制剤、ＡＧＥｓ分解剤、カルボニル化タンパク質分解剤、ニトロ化タンパク質分解剤。 | |
| KR20220090814A (ko) | 등나무 종자추출물을 포함하는 자외선에 의한 피부세포 손상의 예방 또는 개선용 조성물 | |
| KR20210133385A (ko) | 식물성 추출물 기반 바이오 활성화 화장품 조성물 및 이의 제조 방법 | |
| KR20220143996A (ko) | 아이스플랜트 발효물과 캐리어 펩타이드를 포함하는 피부노화 개선용 화장료 조성물 | |
| CN107638374A (zh) | 一种含有何首乌干细胞提取物的抗衰老组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ISP INVESTMENTS INC. Free format text: FORMER APPLICANT(S): AKZO NOBEL CHEMICALS INTERNATIONAL B.V. |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |